Role of rasagiline in treating Parkinson's disease: Effect on disease progression

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 413-419

  Malaty, Irene A ^a   Fernandez, Hubert H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Neuroprotection; Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

AMPHETAMINE DERIVATIVE; CIMETIDINE; ENTACAPONE; LEVODOPA; OMEPRAZOLE; RASAGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ANOREXIA; ARTHRALGIA; ARTHRITIS; BALANCE IMPAIRMENT; CLINICAL TRIAL; DEATH; DEPRESSION; DISEASE COURSE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; INJURY; MELANOMA; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; NEOPLASM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; STROKE; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 77949475271     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793.
2. Fernandez HH, Chen JJ. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol. 2007;30(3):150-168.
3. Dostert PL, Strolin Benedetti M, Tipton KF. Interactions of monoamine oxidase with substrates and inhibitors. Med Res Rev. 1989;9(1):45-89.
4. Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 1992;587(2):241-249.
5. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45(8):878-894.
6. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol. 1989;46(10):1052-1060.
7. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1993;328(3):176-183.
8. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39(1):29-36.
9. Somerset Pharmaceuticals, Inc. Eldepryl [package insert]. Tampa, FL: Somerset Pharmaceuticals, Inc; 1998.
10. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50(4):375-382.
11. Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm. 2003;110(11):1241-1255.
12. Teva Neuroscience, Inc. Azilect [package insert]. Kansas City, MO: Teva Neuroscience, Inc. 2006.
13. Teva Neuroscience, Inc. Azilect (rasagiline) prescribing information [online]. 2007. Accessed on April 14, 2009. Available from: http://www.azilect. eu/streamfile.aspx?filename=smpc.pdf&path=pdf.
14. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132(2):500-506.
15. Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355(3):169-172.
16. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434(3):109-116.
17. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-499.
18. Thebault JK, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24(10):1295- 1305.
19. Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs. 2007;67(12):1725-1747.
20. Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med. 2005;46(10):1618-1624.
21. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-1943.
22. Biglan KM, Schwid S, Eberly S, et al; Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006;21(5):616-623.
23. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-566.
24. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; on behalf of the TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2008;24(4):562-571.
25. Lew M, Hauser R, Hurtig H, Ondo W, Wojcieszek J. Long-term efficacy of rasigiline in Parkinson's disease. Mov Disord. 2005;20(Suppl 10):S75.
26. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-248.
27. Rascol O, Brooks DJ, Melamed E, et al; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954.
28. Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002;109(4):467-481.
29. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004;187(2):455-459.
30. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl. 1998;52:287-300.
31. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106(7-8):593-606.
32. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm. 2001;108(8-9):909-923.
33. Kupsch A, Sautter J, Götz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm. 2001;108(8-9):985-1009.
34. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 1996;47(6 Suppl 3):S161-S170.
35. Chiba K, Trevor A, Castagnoli Jr N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984;120(2):574-578.
36. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79(1-2):172-179.
37. Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci. 2001;939:320-329.
38. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J Neurochem. 2002;82(4):913-923.
39. Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003;66(8):1635-1641.
40. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18(12):1471-1473.
41. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998;9(4):703-707.
42. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport. 2000;11(18):3937-3941.
43. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23(15):2194-2201.
44. Olanow CW, Rascol O. Early rasagaline treatment slows UPDRS decline in the ADAGIO delayed start study. Poster presentation. Madrid, Spain: 12th Congress of European Federation of Neurological Societies. Sept. 23, 2008.
45. deMarcaida JA, Schwid SR, White WB, et al; Parkinson Study Group TEMPO; PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21(10):1716-1721.
46. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48(4):1070-1077.
47. Pahwa R, Factor SA, Lyons KE, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.